Ignite Creation Date:
2024-05-06 @ 7:22 PM
Last Modification Date:
2024-10-26 @ 3:06 PM
Study NCT ID:
NCT05998447
Status:
RECRUITING
Last Update Posted:
2024-03-21
First Post:
2023-08-01
Brief Title:
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
Sponsor:
Genome Company
Organization:
Genome Company
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-09-18
Start Date Type:
ACTUAL
Primary Completion Date:
2026-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-10
Completion Date Type:
ESTIMATED
First Submit Date:
2023-08-01
First Submit QC Date:
August 16 2023
Study First Post Date:
2023-08-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-03-19
Last Update Post Date:
2024-03-21
Last Update Post Date Type:
ACTUAL